B of A Securities Downgrades Sherwin-Williams to Neutral, Lowers Price Target to $292

B of A Securities analyst Steve Byrne downgrades Sherwin-Williams (NYSE:SHW) from Buy to Neutral and lowers the price target from $313 to $292.

byBenzinga Newsdesk

July 13, 2022

1 minute read

B of A Securities analyst Steve Byrne downgrades Sherwin-Williams (NYSE:SHW) from Buy to Neutral and lowers the price target from $313 to $292.

Truist Securities Maintains Buy on Regency Centers, Raises Price Target to $82

By Benzinga Newsdesk

Today, 7:36 AM

Truist Securities analyst Ki Bin Kim maintains Regency Centers (NASDAQ:REG) with a Buy and raises the price target from $75 to $82.

REG

FDA
News

Lilly’s Donanemab Receives U.S. FDA’s Breakthrough Therapy Designation For Treatment Of Alzheimer’s Disease

By Benzinga Newsdesk

Today, 7:36 AM

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE:LLY) investigational antibody therapy for Alzheimer's disease (AD). The

LLY

Comstock Holding Co FY21 Net Income From Continuing Operations $16M vs $2.1M In FY20, Adj. EBITDA $5.8M vs $3.4M Year Over Year, Sales $31.10M Up From $22.50M YoY

By Benzinga Newsdesk

Today, 7:36 AM

Comstock Holding Co (NASDAQ:CHCI) reported $31.10 million in sales this quarter. This is a 38.22 percent increase over sales of $22.50 million the same period last year.

CHCI

Warren Buffett-Backed BYD Sees EV Sales More Than Double In June, Outdoes Rival Nio By 148%

By Rachit Vats

Today, 7:36 AM

Chinese automaker BYD Co Ltd’s (OTC: BYDDF) all-electric vehicle sales more than doubled in June and the company sold more than twice as many electric vehicles as its U.S.-listed rival Nio Inc (NYSE: NIO).

BYDDF

B of A Securities Downgrades Sherwin-Williams to Neutral, Lowers Price Target to $292

Related Posts

Truist Securities Maintains Buy on Regency Centers, Raises Price Target to $82

Lilly’s Donanemab Receives U.S. FDA’s Breakthrough Therapy Designation For Treatment Of Alzheimer’s Disease

Comstock Holding Co FY21 Net Income From Continuing Operations $16M vs $2.1M In FY20, Adj. EBITDA $5.8M vs $3.4M Year Over Year, Sales $31.10M Up From $22.50M YoY

Warren Buffett-Backed BYD Sees EV Sales More Than Double In June, Outdoes Rival Nio By 148%